S
Simon Cawthorn
Researcher at North Bristol NHS Trust
Publications - 71
Citations - 4641
Simon Cawthorn is an academic researcher from North Bristol NHS Trust. The author has contributed to research in topics: Breast cancer & Breast reconstruction. The author has an hindex of 25, co-authored 71 publications receiving 4178 citations. Previous affiliations of Simon Cawthorn include Southmead Hospital & National Health Service.
Papers
More filters
Journal ArticleDOI
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.
Jack Cuzick,John F. Forbes,Rhiannon Tudor Edwards,Michael J. Baum,Simon Cawthorn,Alan S. Coates,A Hamed,A Howell,Thomas Powles +8 more
TL;DR: Prophylactic use of tamoxifen is contraindicated in women at high risk of thromboembolic disease and the combined evidence indicates that mortality from non-breast-cancer causes is not increased by tamoxIFen.
Journal ArticleDOI
Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer—96-Month Follow-up of the Randomized IBIS-I Trial
TL;DR: The prophylactic effect of tamoxifen was fairly constant for the entire follow-up period, and no diminution of benefit was observed for up to 10 years after randomization, but side effects in the tamoxIFen group were much lower after completion of the active treatment period than during active treatment.
Journal ArticleDOI
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial
Jack Cuzick,Ivana Sestak,John F. Forbes,Mitch Dowsett,Jill Knox,Simon Cawthorn,Christobel Saunders,Nicola Roche,Robert E. Mansel,Gunter von Minckwitz,Bernardo Bonanni,Tiina Palva,Anthony Howell +12 more
TL;DR: Anastrozole effectively reduces incidence of breast cancer in high-risk postmenopausal women, and the fact that most of the side-effects associated with oestrogen deprivation were not attributable to treatment, provides support for the use of anastroZole in post menopausal women at high risk of Breast cancer.
Journal ArticleDOI
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study
Robert E. Coleman,LM Banks,Samia I. Girgis,Lucy Kilburn,Eduard Vrdoljak,John N. Fox,Simon Cawthorn,Ashraf Patel,Claire Snowdon,Emma Hall,Judith M Bliss,R. Charles Coombes +11 more
TL;DR: These results indicate that the increase in survival shown previously with the IES switch strategy is achieved at the expense of some detriment to skeletal health, so the risk-benefit ratio to women needs to be individually assessed.
Journal ArticleDOI
Tamoxifen-Induced Reduction in Mammographic Density and Breast Cancer Risk Reduction: A Nested Case–Control Study
Jack Cuzick,Jane Warwick,Elizabeth Pinney,Stephen W. Duffy,Simon Cawthorn,Anthony Howell,John F. Forbes,Ruth Warren +7 more
TL;DR: The 12- to 18-month change in mammographic breast density is an excellent predictor of response to tamoxifen in the preventive setting.